Exhibit 10.1
ADVISOR AGREEMENT
This Advisor Agreement (“Agreement”) is entered into as of April 22, 2023 (the “Effective Date”) between Kezar Life Sciences, Inc. (the “Company”), a Delaware corporation, and Christopher Kirk, Ph.D. (“Consultant”). Company and the Consultant are referred to herein individually as “Party,” and collectively as the “Parties.”
Whereas, Consultant resigned from his position as President and Chief Scientific Officer of the Company, effective April 21, 2023 (the “Resignation Date”), and the Company wishes to retain Consultant as a Scientific and Strategic Advisor; and
Whereas, Consultant is also serving as a non-employee member of the Company’s Board of Directors.
Now, Therefore, the Parties hereby agree as follows:
1
2
3
4
5
[Remainder of Page Left Blank]
6
In Witness Whereof, the Parties have executed this Agreement as of the Effective Date.
Christopher Kirk, Ph.D.
By: /s/ Christopher Kirk
Kezar Life Sciences, Inc.
By: /s/ John Fowler
John Fowler
Chief Executive Officer
7